With the wild success of glucagon-like peptide-1 (GLP-1) drugs, Amylyx Pharmaceuticals is looking to explore the field as it has bought out avexitide, a Phase III ready GLP-1 receptor antagonist, for $35 million in an auction last month from bankrupt Eiger BioPharmaceuticals
Laboratory measures included low-density lipoprotein cholesterol (LDL-c), triglycerides (TG), high-density lipoprotein cholesterol (HDL-c), total cholesterol (TC), serum creatinine (Scr), estimated glomerular filtration rate (eGFR), osteocalcin (OCN), vitamin D (VitD), and hemoglobin A1c (HbA1c), all of which were obtained from routine clinical testing
The Warburg effect then and now: from cancer to inflammatory diseases
The 14 peptides remain Category 2 substances today and they are not currently eligible for routine 503A compounding despite certain public commentary